Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Open accessPublished version of a preprint
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Background: Quinoline-derived metabolites exhibit notable chemical complexity. What causes minor structural alterations to induce significant changes in disease outcomes? Historically, eclipsed by more straightforward scaffolds, these chemicals serve as a dynamic hub in tryptophan metabolism, linking immunomodulation, excitotoxicity, and cancer. However, many of these compounds struggle to cross the blood–brain barrier, and we still do not fully understand how certain structural changes affect their bioavailability or off-target effects. Thus, contemporary research highlights halogenation, esterification, and computational modeling to enhance structure–activity relationships. Summary: This narrative review emphasizes the integration of rational drug design, multi-target ligands, and prodrug methods in enhancing quinoline scaffolds. We explore each molecule’s therapeutic promise, refine each scaffold’s design, and develop each derivative to maximize clinical utility. Translating these laboratory findings into clinical practice, however, remains a formidable challenge. Conclusions: Through the synthesis of findings regarding NMDA receptor antagonism, improved oral bioavailability, and reduced metabolic instability, we demonstrate how single-site changes might modulate excitotoxicity and immunological signaling. Advancing quinoline-based medicines will yield significant advancements in neurology, psychiatry, and oncology. This enlarged framework fosters collaborative discovery, engages various audiences, and advances the field towards next-generation disease-modifying therapies. Robust preclinical validation, patient classification, and comprehensive toxicity evaluations are crucial stages for achieving these extensive endeavors and fostering future therapeutic discoveries globally.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress and autophagy: The clash between damage and metabolic needs
Filomeni, G., De Zio, D., & Cecconi, F. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.150 · Cited by 2,195
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586 · cited 1×
“This table traces the progression from classic antimalarials to contemporary antibiotics, emphasizing how structural changes shape e ffi cacy, safety pro fi les, and clinical relevance.”
Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health
Cervenka, I., Agudelo, L. Z., & Ruas, J. L. (2017) · Science · doi:10.1126/science.aaf9794 · Cited by 1,382 · cited 2×
“Among the most scrutinized products are kynurenic acid (KYNA) and quinolinic acid (QUIN), which play critical roles in modulating neurotransmission, safeguarding neurons, and orchestrating immune responses [3].”
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects
Badawy, A. A.-B. (2017) · International Journal of Tryptophan Research · doi:10.1177/1178646917691938 · Cited by 1,158 · cited 2×
“…or misregulation of these compounds can fuel diverse pathologies, spanning neurodegenerative conditions, psychiatric disorders, and Remarkably, these metabolites appear across many species and have preserved their functional importance for millions of years [6]. even certain cancers [5].”
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138 · cited 1×
“This table traces the progression from classic antimalarials to contemporary antibiotics, emphasizing how structural changes shape e ffi cacy, safety pro fi les, and clinical relevance.”
Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications
Liu, Z., Zhou, T., Ziegler, A. C., Dimitrion, P., & Zuo, L. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2525967 · Cited by 810
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Zhou, Y., Zhang, Y., Lian, X., Li, F., Wang, C., Zhu, F., Qiu, Y., & Chen, Y. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab953 · Cited by 665
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Self-citationTryptophan metabolism and gut-brain homeostasis
Roth, W., Zadeh, K., Vekariya, R., Ge, Y., & Mohamadzadeh, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062973 · Cited by 519 · cited 2×
“…are kynurenic acid (KYNA) and quinolinic acid (QUIN), which play critical roles in modulating neurotransmission, safeguarding neurons, and orchestrating Under normal conditions, these molecules help maintain the delicate balance that protects and regulates neural function [4]. immune responses [3].”
Quinolinic acid: an endogenous neurotoxin with multiple targets
Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393 · cited 4×
“Despite their diverse biological activities, translating endogenous quinoline-based compounds into therapeutic interventions faces significant hurdles [109].”
InfluentialThe kynurenine pathway and neurodegenerative disease
Maddison, D. C., & Giorgini, F. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.03.002 · Cited by 309
The therapeutic potential of targeting tryptophan catabolism in cancer
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300 · cited 1×
“In recent years, therapeutic strategies targeting Trp metabolism have drawn increased attention, supported by encouraging preclinical findings and a rise in clinical trials [24,25].”
Xiong, B., Wang, Y., Chen, Y., Xing, S., Liao, Q., Chen, Y., Li, Q., Li, W., & Sun, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00910 · Cited by 232
Hara, N., Yamada, K., Shibata, T., Osago, H., Hashimoto, T., & Tsuchiya, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610357200 · Cited by 205
Mithaiwala, M. N., Santana-Coelho, D., Porter, G. A., & O’Connor, J. C. (2021) · Cells · doi:10.3390/cells10061548 · Cited by 190
S100 Proteins in Alzheimer’s Disease
Cristóvão, J. S., & Gomes, C. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00463 · Cited by 188
Lipid nanoparticle-mediated drug delivery to the brain
Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E. L., & S Manickam, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114861 · Cited by 187
Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?
Van den Eynde, B. J., van Baren, N., & Baurain, J.-F. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033635 · Cited by 175
Valotto Neto, L. J., Reverete de Araujo, M., Moretti Junior, R. C., Mendes Machado, N., Joshi, R. K., dos Santos Buglio, D., Barbalho Lamas, C., Direito, R., Fornari Laurindo, L., Tanaka, M., et al. (2024) · Antioxidants · doi:10.3390/antiox13040393 · Cited by 146
Self-citationKynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142
Tryptophan metabolism: Mechanism-oriented therapy for neurological and psychiatric disorders
Li, D., Yu, S., Long, Y., Shi, A., Deng, J., Ma, Y., Wen, J., Li, X., Liu, S., Zhang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.985378 · Cited by 129 · cited 2×
“…conditions, these molecules help maintain the delicate balance that protects and regulates However, an overabundance or misregulation of these compounds can fuel diverse pathologies, spanning neurodegenerative conditions, psychiatric disorders, and even certain cancers [5]. neural function [4].”
Isaacs, J. T., Antony, L., Dalrymple, S. L., Brennen, W. N., Gerber, S., Hammers, H., Wissing, M., Kachhap, S., Luo, J., Xing, L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2730 · Cited by 116
Wang, Z., Hu, J., Yang, X., Feng, X., Li, X., Huang, L., & Chan, A. S. C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01417 · Cited by 91
Wang, Q., Li, W.-X., Dai, S.-X., Guo, Y.-C., Han, F.-F., Zheng, J.-J., Li, G.-H., & Huang, J.-F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161032 · Cited by 88 · cited 1×
“Summarize each motif (e.g., Cl, F, sulfonamide) and its known effects on receptor affinity or metabolism.”
Metropulos, A. E., Munshi, H. G., & Principe, D. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104380 · Cited by 81
Repurposed agents in the Alzheimer’s disease drug development pipeline
Bauzon, J., Lee, G., & Cummings, J. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00662-x · Cited by 77 · cited 1×
“Repurposing these compounds also accelerates clinical testing by leveraging existing safety and pharmacokinetic data [32].”
Park, L. T., Kadriu, B., Gould, T. D., Zanos, P., Greenstein, D., Evans, J. W., Yuan, P., Farmer, C. A., Oppenheimer, M., George, J. M., et al. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa025 · Cited by 63
Poles, M. Z., Nászai, A., Gulácsi, L., Czakó, B. L., Gál, K. G., Glenz, R. J., Dookhun, D., Rutai, A., Tallósy, S. P., Szabó, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717157 · Cited by 49
Self-citationTanaka, M. (2025) · doi:10.20944/preprints202412.0679.v2 · Cited by 42
Self-citationTanaka, M. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/197425 · Cited by 27
Self-citationAdipoRon’s Impact on Alzheimer’s Disease—A Systematic Review and Meta-Analysis
Barbalho, S. M., Laurindo, L. F., de Oliveira Zanuso, B., da Silva, R. M. S., Gallerani Caglioni, L., Nunes Junqueira de Moraes, V. B. F., Fornari Laurindo, L., Dogani Rodrigues, V., da Silva Camarinha Oliveira, J., Beluce, M. E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020484 · Cited by 18
Self-citation
Cited by
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57
Self-citationFrom Microbial Switches to Metabolic Sensors: Rewiring the Gut–Brain Kynurenine Circuit
Tanaka, M., & Vécsei, L. (2025) · doi:10.20944/preprints202506.0880.v1 · Cited by 24
Self-citationFrom Biomarkers to Behavior: Mapping the Neuroimmune Web of Pain, Mood, and Memory
Tanaka, M., & Battaglia, S. (2025) · Biomedicines · doi:10.3390/biomedicines13092226 · Cited by 13
Self-citationTanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Self-citationNeurogenesis and Neuroinflammation in Dialogue: Mapping Gaps, Modulating Microglia, Rewiring Aging
Tanaka, M. (2026) · Cells · doi:10.3390/cells15010078 · Cited by 11
“Critical milestones include demonstrating long-term safety, reproducibility, and circuit specificity, ensuring that reprogramming interventions translate effectively into clinically viable therapies [163,358].”
Self-citation
Metadata
- Authors
- Tanaka, M., Szatmári, I., & Vécsei, L.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2025-04-22
- Volume
- 18
- Issue
- 5
- Pages
- 607
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W4409668526
- Cited by
- 29
- References
- 34
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.